The europe cardiac monitoring market size is projected to expand from USD 7.91 billion in 2025 and USD 8.47 billion in 2026 to USD 11.97 billion by 2031, registering a CAGR of 7.16% between 2026 to 2031. This report is Segmented by Product Type (ECG Devices, Holter Monitors, Event Recorders, Mobile Cardiac Telemetry, Implantable Loop Recorders, Smart Wearable Monitors), End User (Hospitals, Cardiac Centers & Clinics, Home-Care Settings, Ambulatory Surgical Centers, Others), and Geography (Germany, United Kingdom, and More). The Market Forecasts are Provided in Terms of Value (USD).
The Europe cardiac monitoring market size for implantable solutions is poised to expand as regulatory guidance now treats AI algorithms as Class IIb devices, permitting software-only vendors to partner with hardware OEMs. Cardiologs, for example, licensed its arrhythmia-detection engine to three manufacturers in 2024, embedding predictive analytics natively and shrinking post-processing times. Competitive differentiation is therefore shifting from hardware ergonomics to cloud interoperability and analytic accuracy.
Europe Cardiac Monitoring Market Trends and Insights
Rising Prevalence of CVD Among Europe’s Ageing Population
Cardiovascular disease claimed 1.7 million European lives in 2024, equal to 42.5% of all regional deaths. The Safe Hearts Plan mandates risk screening for adults over 40 by 2028, expanding the candidate pool for continuous rhythm surveillance. Hypertension control rates stand at only 38% across the EU, revealing an unmet need that wearable and patch-based ECG can address. Eurostat projects seniors (≥ 65 years) will rise to 24.8% of the EU population by 2030 concentrating demand in Germany, Italy, and Spain. Vendors that position devices as chronic-disease-management tools rather than episodic diagnostics are poised to benefit from capitated payment models that reward outcomes.Shift Toward Ambulatory and Remote Cardiac Monitoring
Payment incentives are migrating from inpatient to outpatient settings. Germany’s Hospital Reform Act moved select cardiac procedures into flat-rate bundles that financially encourage early discharge. In the United Kingdom, the 2025/26 Payment Scheme set separate tariffs for ambulatory BP monitoring and Pro-BNP testing, formally recognizing diagnostics performed outside hospital walls. France’s August 2025 intra-DRG update now pays higher rates when remote telemetry triggers clinical action. These changes redirect purchasing power toward mobile cardiac telemetry and event recorders, forcing manufacturers to cultivate payer relationships and validate cost-per-diagnosis advantages.Other drivers and restraints analyzed in the detailed report include:
- Technological Advances in Wearable ECG Devices
- Favorable DRG and National Tariff Updates
- Stringent EU-MDR Compliance Costs
- Data-Privacy Hurdles Under GDPR
Segment Analysis
ECG devices accounted for 40.1% of Europe's cardiac monitoring market share in 2025, underpinned by hospital demand for 12-lead systems.. Yet smart wearable monitors are projected to post a 7.81% CAGR to 2031, outpacing every other category. This surge reflects FDA-cleared consumer devices such as Apple Watch Series 10 and Samsung Galaxy Watch 7 that push diagnostics closer to the patient. Holter monitors remain relevant for 24- to 48-hour studies, but extended-wear patches offering 14-day recordings are eroding demand. Mobile cardiac telemetry, which delivers real-time data over 30 days, bridges the gap between ambulatory patches and implantable loop recorders, the latter commanding premium pricing above USD 3,000 per unit. Boston Scientific’s Bluetooth-enabled LUX-Dx II+ extends battery life to 4.5 years, reducing replacement procedures and aligning with value-based quotas.The Europe cardiac monitoring market size for implantable solutions is poised to expand as regulatory guidance now treats AI algorithms as Class IIb devices, permitting software-only vendors to partner with hardware OEMs. Cardiologs, for example, licensed its arrhythmia-detection engine to three manufacturers in 2024, embedding predictive analytics natively and shrinking post-processing times. Competitive differentiation is therefore shifting from hardware ergonomics to cloud interoperability and analytic accuracy.
Complete Report Scope:
- By Product Type
- ECG Devices
- Holter Monitors
- Event Recorders
- Mobile Cardiac Telemetry
- Implantable Loop Recorders
- Smart Wearable Monitors
- By End User
- Hospitals
- Cardiac Centres & Clinics
- Home-Care Settings
- Ambulatory Surgical Centres
- Others
- By Country
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
List of Companies Covered in this Report:
- Abbott Laboratories
- AliveCor
- Baxter
- BIOTRONIK
- Bittium Corporation
- Boston Scientific
- Cardiologs Technologies SAS
- GE HealthCare Technologies Inc.
- iRhythm Technologies
- Koninklijke Philips
- Lepu Medical
- LivaNova
- Medtronic
- MicroPort
- Mindray
- Nihon Kohden
- Preventice Solutions
- Schiller
- Spacelabs Healthcare (OSI Systems)
- Vectorious Medical Technologies
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AliveCor Inc.
- Baxter International Inc
- Biotronik SE & Co. KG
- Bittium Corporation
- Boston Scientific Corporation
- Cardiologs Technologies SAS
- GE HealthCare Technologies Inc.
- iRhythm Technologies Inc.
- Koninklijke Philips N.V.
- Lepu Medical Technology
- LivaNova PLC
- Medtronic plc
- MicroPort Scientific
- Mindray Medical International Ltd.
- Nihon Kohden Corporation
- Preventice Solutions Inc.
- Schiller AG
- Spacelabs Healthcare (OSI Systems)
- Vectorious Medical Technologies
